CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Left Ventricular Assist Device as a Bridge to Recovery for Patients With Advanced Heart Failure Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction HFpEF: From Mechanisms to Therapies Left Ventricular Assist Devices for Lifelong Support

Clinical TrialVolume 71, Issue 11 Supplement, March 2018

JOURNAL:J Am Coll Cardiol. Article Link

Comparison Of High Shear Stress-Induced Thrombotic And Thrombolytic Effect Between Aspirin, Clopidogrel And Very Low Dose Rivaroxaban And Aspirin, Ticagrelor Treatments In Patients With Acute Coronary Syndrome

M Kim, KS Hyuk, JJ Park et al. Keywords: high shear stress; global thrombosis test;

ABSTRACT


BACKGROUND - Global thrombosis test (GTT) is a simple but useful method to measure high shear stress-induced whole blood thrombotic and endogenous thrombolytic activity and it may mimic platelet aggregation in acute coronary syndrome (ACS) condition more accurately compared to conventional platelet function tests. We compared GTT and conventional platelet function test (VerifyNow® test) in patients with ACS who were treated aspirin/ticagrelor (TICA) or aspirin/clopidogrel/very low dose rivaroxaban (RIVA).


METHODS - A total of 41 patients (TICA (n=24), RIVA (n=17)) who underwent percutaneous coronary intervention were consecutively enrolled. GTT and VerifyNow®test were performed at day 2 (D2) and day 30 (D30) after successful PCI. We compared occlusion time (OT), lysis time (LT), aspirin reaction unit (ARU) and P2Y12 reaction unit (PRU) between the two groups at D2 and D30.


RESULTS - There were no significant statistical differences in baseline clinical, angiographic and laboratory characteristics between the two groups. At D2, there were no significant differences in OT (483.5±94.4 sec vs. 540.1±146.2 sec, p=0.239), LT (1,952.2±1,420.9 sec vs. 1,919.2±1,125.4 sec, p=0.253) or ARU (490.0±79.3 vs. 455.9±73.3, p=0.102), but PRU was significantly lower in the TICA group (34.8±60.1 vs. 130.9±70.6, p<0.001). At D30, there were no significant differences in OT (553.5±111.1 sec vs. 634.2±152.0 sec, p=0.121), LT (1540.7±704.1 sec vs. 1679.2±529.4 sec, p=0.261) or ARU (441.4±83.9 vs. 468.8±69.7, p=0.144) between two groups, and PRU was consistently lower in the TICA group (34.6±36.1 vs. 164.8±70.6, p<0.001).


CONCLUSION - High shear stress-induced global thrombotic and lytic activity did not differ between the two antithrombotic regimens although TICA showed more potent inhibition of ADP-induced platelet aggregation.